ATYR · aTyr Pharma, Inc.

aTyr Pharma's Q1 2026 results showed improved financial performance with consolidated net loss narrowing to $10.8 million or $0.11 per share from $14.9 million or $0.17 per share in Q1 2025, driven by a 38% reduction in R&D expenses to $7.3 million primarily from costs associated with the Phase 3 EFZO-FIT™ and Phase 2 EFZO-CONNECT™ studies, alongside preclinical efforts. G&A expenses rose modestly to $4.1 million. Cash position stood at $68.3 million as of March 31, 2026, down from $80.9 million at year-end 2025, supporting ongoing operations. CEO Sanjay Shukla highlighted a clear path forward for efzofitimod in pulmonary sarcoidosis post-Type C FDA meeting, planning an IND filing in June 2026 for a global Phase 3 trial in ~372 patients with chronic symptomatic disease and restrictive lung impairment. The 54-week study will use 5.0 mg/kg IV efzofitimod every 3 weeks versus placebo, with FVC change at week 48 as primary endpoint and KSQ-Lung score as key secondary, on stable background corticosteroids/immunosuppressants. Enrollment in the Phase 2 EFZO-CONNECT™ in SSc-ILD remains on track for H1 2026 completion, building on promising 2025 interim data. A poster on preclinical candidate ATYR0101 was accepted for presentation in June 2026, detailing its fibrosis-reducing mechanism via LTBP-1 interaction.